Showing results (1-10 of 108) with videos related to
Sort By:
Pageof 11
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure controlAmos Pines, Enrique Z FismanCurrent Hypertension Reports|November 7, 2002
Systemic hypertension in postmenopausal women: a clinical approachEnrique Z Fisman, Alexander Tenenbaum, Amos PinesThe American Journal of Geriatric Cardiology|November 1, 1995
Rehabilitation in Older Coronary PatientsItzha Shapira, Enrique Z. Fisman, Michael Motro, et al.Cardiovascular Diabetology|January 29, 2011
"The metabolic syndrome... is dead": these reports are an exaggerationAlexander Tenenbaum, Enrique Z FismanCardiovascular Diabetology|December 3, 2004
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?Alexander Tenenbaum, Enrique Z FismanCardiology Journal|August 6, 2013
Optimal revascularization in diabetes after the FREEDOM trial: were the controversies finally settled?Alexander Tenenbaum, Enrique Z FismanCardiovascular Diabetology|November 25, 2021
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospectEnrique Z Fisman, Alexander TenenbaumCardiovascular Diabetology|September 30, 2015
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesEnrique Z Fisman, Alexander TenenbaumCardiovascular Diabetology|November 16, 2012
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Alexander Tenenbaum, Enrique Z FismanCardiovascular Diabetology|October 13, 2010
The ubiquitous interleukin-6: a time for reappraisalEnrique Z Fisman, Alexander TenenbaumPageof 11